So excited about this now, looking forward to #lupus2024 Bruges 2024! 🤓 Grateful for my supervisors for the work and the opportunities ✨✨
I love my circle crew bunches! If you didn't make it, I love you too!! 💋💜
#TwitterCircle
#LUPUS2024
#LupusAdvocate
Such a pleasure to be able to present the results from the LUPHPOS survey at the #Lupus2024 🦋
Thank you for all the support and dissemination of the survey 🌟
Let's work to refine the optimal use of GCs in SLE and minimize the risk of steroid-associated damage 💪
#Lupus2024 Day I in the beautiful concert hall in Bruges 🇧🇪 learning about the benefits and difficulties when treating SLE patients with HCQ. Adherence is 🔑 and blood monitoring should be implemented to find the ideal dosage 💡
Biological therapy during pregnancy in SLE?
#lupus2024 #Belimumab #Rituximab #Anifrolumab #voclosporin
👉 #lupus2024
Amazing debate between the legendary Prof Michelle Petri and David Isenberg: Does a minority or a majority of SLE need a biologic ? 🦋
🔺Results: 53% voted majority and 47% minority
After the exciting #lupus2024 super excited to have poster selected for poster tour at #eular2024 thanks Chris Wincup, Eman and Kings team!! #Sle #Globalsteroids #abstracts
See you in Vienna!!
Very important message from Ioannis Parodis at #SLEuro #Lupus2024 meeting - Even low doses of steroids cause side effects! We need to 🎯 0!
Early use of biologics discussed as an option to achieve this! 🔥
A magnificent debate between profs
Petri & Isenberg: Will a majority or a minority of #Lupus patients require use of #biologics ? Looks like a tie for now, time will tell….. #LUPUS2024 #Rheumatology SLEuro
Excellent overview by Maria Tektonidou on the risk of #cardiovascular disease in #APS and #Lupus . Risk prediction is flawed in traditional algorithms. Conscientious monitoring of traditional and disease-related risk factors is crucial in risk reduction. #LUPUS2024 SLEuro
✅The majority of SLE patients reported being in an acceptable symptom state according to the PASS question
✅More than a third of patients in the PASS group were not in remission/LLDAS
✅Approximately 10-35% of
the non-PASS group were in a state of remission/LLDAS
#lupus2024